Abstract:Background: Ovarian cancer is the most fatal gynecologic malignancy worldwide due to its vagueness, delay in diagnosis, recurrence, and drug resistance. Therefore, a new type of ovarian cancer treatment prediction biomarker is urgently needed to supplement existing tools. A total of 230 people participated in this study. Out of this figure, 100 participants were patients who underwent an ovarian tumor operation, another 100 participants were ovarian benign patients, and the remaining 30 participants were healthy women. Cancer (experimental) group were 100 patients who underwent ovarian tumor operation, while the control groups were 130 participants consisting of 100 ovarian benign patients and 30 healthy women. Levels of SAA, carbohydrate antigen-125 (CA-125), and human epididymis protein 4 (HE4) were assessed using standard laboratory protocols. A total of 5 ovarian cancer tissues and paracancerous tissues were collected and then stored at - 80 °C until the qRT-PCR assay was conducted. Results: The ROC curve of SAA concentration in ovarian cancer was plotted to obtain the area under the curve AUC = 0.889, the cut-off value 17.05 mg/L, the sensitivity 78.4% and specificity 86.5%. Compared with pretreatment, the level of serum SAA decreased significantly after treatment. The results revealed that there was a significant correlation between the level of serum SAA and advanced FIGO stage, histology subtype, lymphatic invasion, and distant metastasis (p = 0.003,0.002,0.000 and 0.001). The quantitative Reverse transcription polymerase chain reaction (qRT-PCR) assay revealed that the Messenger RNA (mRNA) of SAA-1 and SAA-4 was much higher in cancer tissues than in adjacent tissues, and MMPs was up-regulation including MMP-1, MMP-9 and MMP- 12 in OVCAR-3 cell stimulated by SAA. The transwell assay revealed that SAA could promote OVCAR-3 cell migration. Moreover, SAA can regulate EMT markers and promote AKT pathway activation. Conclusions: In summary, our results demonstrated that SAA may be a potential diagnosis and treatment prediction biomarker. The SAA promotes OVCAR-3 cell migration by regulating MMPs and EMT which may correlate with AKT pathway activation.

LC-MS/MS Analysis of Ovarian Cancer Metastasis-Related Proteins Using a Nude Mouse Model: 14-3-3 Zeta As a Candidate Biomarker.

SCREENING AND IDENTIFICATION OF SERUM BIOMARKERS OF OVARIAN CARCINOMA BY THE TRANSPLANTED TUMOR IN NUDE MOUSE AS THE MODEL

Deep Depletion of Abundant Serum Proteins Reveals Low-Abundant Proteins As Potential Biomarkers for Human Ovarian Cancer

Effects of Dynein Light Chain Tctex-type 3 on the Biological Behavior of Ovarian Cancer

Alterations in the serum proteome profile during the development of ovarian cancer

The ovarian cancer-derived secretory/releasing proteome: A repertoire of tumor markers.

Dynamic changes in the urine proteome in two ovarian cancer rat models

Peptidome Characterization of Ovarian Cancer Serum and the Identification of Tumor Suppressive Peptide ZYX36-58

Proteomic and Lipidomic Analysis of Exosomes Derived from Ovarian Cancer Cells and Ovarian Surface Epithelial Cells.

Identification of Lymphatic Metastasis-Associated Genes in a Metastatic Ovarian Cancer Cell Line

Identification of Cathepsin K in the Peritoneal Metastasis of Ovarian Carcinoma Using In-silico, Gene Expression Analysis

Serum amyloid a, a potential biomarker both in serum and tissue, correlates with ovarian cancer progression

Discovery of serum biomarkers implicated in the onset and progression of serous ovarian cancer in a rat model using iTRAQ technique

Identification of metastasis-associated proteins of ovarian cancer by proteomics

Identification of Metastasis-Related Proteins and Their Clinical Relevance to Triple-Negative Human Breast Cancer

[Identification of Two Potential Serum Biomarkers for Ovarian Cancer and Clinical Validation Thereof].

Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer.

Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics

Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses

Use of Plasma Metabolomics to Identify Diagnostic Biomarkers for Early Stage Epithelial Ovarian Cancer.

Identification of Candidate Biomarkers for Epithelial Ovarian Cancer Metastasis Using Microarray Data